Wave Life Sciences (WVE), a clinical-stage biotechnology company, on Thursday initiated the Phase 1 INLIGHT clinical trial for WVE-007, a novel, long-acting RNA-based therapeutic aimed at treating obesity.
WVE-007 is a GalNAc-conjugated small interfering RNA or siRNA designed to target INHBE mRNA, a genetically validated target that could enable healthy weight loss by promoting fat burning while preserving muscle mass.
This innovative treatment approach has the potential for once- or twice-yearly dosing and could significantly address the global obesity epidemic, affecting over 1 billion people.
The INLIGHT trial will enroll adults with overweight or obesity to evaluate the safety, tolerability, pharmacokinetics, and efficacy of WVE-007.
Results are expected in 2025, with proof-of-concept clinical data focused on fat loss, muscle preservation, and improved metabolic health.
WVE-007 is Wave Life Sciences' first siRNA therapeutic to enter clinical development, marking a significant advancement in RNA interference technology and its application to common diseases like obesity.
Currently, WVE is trading at $12.23 down by 0.57%.
For comments and feedback: editorial@rttnews.com